血清LncRNA MALAT1和microRNA-124水平检测对非小细胞肺癌患者预后的评估价值

The prognostic value of serum LncRNA MALAT1 and microRNA-124 levels in non-small cell lung cancer patients

目的:探究长链非编码RNA-转移相关肺腺癌转录本1(LncRNA MALAT1)和微小RNA-124(microRNA-124)对非小细胞肺癌(NSCLC)患者预后的预测效能。方法:选取2020年06月至2022年06月我院收治的124例NSCLC患者作为研究对象,入院后,收集患者的病历资料,检测入院时外周血LncRNA MALAT1、microRNA-124的相对表达量。电话随访12个月记录患者的死亡率,分为生存组和死亡组,分析NSCLC患者预后的影响因素,评估血清LncRNA MALAT1、microRNA-124对NSCLC患者预后的预测效能。结果:死亡组患者的IV期占比及LncRNA MALAT1相对表达量高于生存组,microRNA-124相对表达量低于生存组。Logistic遂步分析显示,病理分期IV期(OR=12.342,95%CI:4.295~36.765)、LncRNA MALAT1(OR=5.371,95%CI:1.836~15.714)及microRNA-124(OR=0.257,95%CI:0.089~0.752)是NSCLC患者死亡的影响因素(P<0.05)。LncRNA MALAT1与microRNA-124呈负相关(P<0.05)。受试者工作特性曲线(ROC)分析显示,LncRNA MALAT1及microRNA-124单一及联合预测NSCLC患者预后的灵敏度分别为0.741(95%CI:0.601~0.846)、0.759(95%CI:0.621~0.861)、0.815(95%CI:0.682~0.903),特异度分别为0.825(95%CI:0.705~0.906)、0.762(95%CI:0.635~0.856)、0.841(95%CI:0.723~0.917),曲线下面积(AUC)分别为0.781、0.760、0.839。联合预测效能更高(P<0.05)。结论:LncRNA MALAT1及microRNA-124可用于预测NSCLC患者的预后,且预测效能良好。

Objective:To exploring the predictive efficacy of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1(LncRNA MALAT1)combined with microRNA-124 in predicting the prognosis of non-small cell lung cancer(NSCLC)patients.Methods:124 NSCLC patients admitted to in our hospital between June 2020 and June 2022 were selected as the study subjects.After admission,the patient's medical records were collected and the relative expression of LncRNA MALAT1 and microRNA-124 in peripheral blood was detected.Record the mortality rate of patients during a 12 month follow-up by phone,divide them into survival group and death group,analyze the influencing factors of prognosis in NSCLC patients,and evaluate the predictive efficacy of serum LncRNA MALAT1 and microRNA-124 on the prognosis of NSCLC patients.Results:The proportion of patients in stage IV and the relative expression of LncRNA MALAT1 in the death group were higher than those in the survival group,while the relative expression of microRNA-124 was lower than that in the survival group.Logistic stepwise analysis showed that pathological stage IV(OR=12.342,95%CI:4.295~36.765),LncRNA MALAT1(OR=5.371,95%CI:1.836~15.714),and microRNA-124(OR=0.257,95%CI:0.089~0.752)were influencing factors for mortality in NSCLC patients(P<0.05).There was a negative correlation between LncRNA MALAT1 and microRNA-124(P<0.05).The receiver operating characteristic curve(ROC)analysis showed that the sensitivity of LncRNA MALAT1 and microRNA-124 in predicting the prognosis of NSCLC patients was 0.741(95%CI:0.601~0.846),0.759(95%CI:0.621~0.861),0.815(95%C I:0.682~0.903),and the specificity was 0.825(95%CI:0.705~0.906),0.762(95%CI:0.635~0.856),and 0.841(95%CI:0.723~0.917),respectively.The area under the curve(AUC)is 0.781,0.760,and 0.839,respectively.The joint prediction efficiency was higher(P<0.05).Conclusion:LncRNA MALAT1 and microRNA-124 can be used to predict the prognosis of NSCLC patients,and their predictive efficacy is good.